Business ❯ Finance ❯ Mergers and Acquisitions

Pharmaceuticals

Obesity Drugs Oncology Biotech Companies Torrent Pharmaceuticals Walgreens Business Sale Biotechnology 23andMe Supernus Pharmaceuticals Immunology Rare Diseases Biontech-Curevac Acquisition Company Acquisitions COPD Treatments Pfizer Inc. Gene Therapy Cardiovascular Drugs Anti-obesity Drugs Ophthalmology Antitrust Issues Pfizer Industry Trends Market Impact JB Chemicals Regulatory Approval Legal Disputes Bidding Wars Evoke Pharma, Inc. Novo Nordisk Sanofi Metsera Alkermes and Avadel Pharmaceuticals Novo Holdings Acquisition Neurological Disorders

Lundbeck Challenges Alkermes With Up to $23-Per-Share Offer for Avadel

Analysts say the richer bid pressures Alkermes to decide its next move.

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

Pfizer Clinches $10 Billion Metsera Deal After Novo Nordisk Withdraws

Metsera Backs Pfizer’s $10 Billion Deal, Citing Regulatory Risks in Novo Bid

Pfizer Wins Early U.S. Antitrust Clearance for Metsera Deal as Novo’s Higher Bid Pressures Timeline

Lilly to Buy Adverum in Gene‑Therapy Deal Worth Up to $12.47 a Share

Alkermes to Buy Avadel in Up to $2.1 Billion Deal With CVR Tied to Lumryz Expansion